Acura Pharmaceuticals Announces Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results

PALATINE, IL --(Marketwired - November 03, 2014) - Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014.

The Company reported a net loss of $2.9 million for the third quarter 2014 or $0.06 per diluted share, compared to net loss of $3.2 million or $0.07 per diluted share for the same period in 2013. Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $1.0 million in the third quarter 2014, compared to $1.3 million for the same period in 2013. Selling, marketing, general and administrative expenses were $1.7 million in the third quarter 2014, versus $1.9 million in the same period last year. Selling and marketing expenses primarily consist of advertising and marketing activities for NEXAFED®.

The Company reported net losses of $10.5 million and $0.22 per diluted share for each of the nine months ended 2014 and 2013. Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $3.7 million in the nine months ended 2014, compared to $4.1 million for the same period in 2013. Selling, marketing, general and administrative expenses were $5.9 million in the nine months ended 2014, versus $6.1 million in the same period last year. Selling and marketing expenses primarily consisted of advertising and marketing activities for NEXAFED®.

As of October 30, 2014, the Company had cash, cash equivalents and marketable securities of $14.0 million and had $10.0 million in term debt financing.

We launched NEXAFED® commercially in mid-December 2012. Given the limited sales history of NEXAFED®, we could not reliably estimate expected returns of the product at the time of shipment. Accordingly, we have deferred recognition of revenue and the related cost of sales on selected product shipments of NEXAFED® until the right of return no longer exists or adequate history and information is available to estimate product returns. At September 30, 2014 we have deferred $228 thousand of revenue from shipments of NEXAFED®. During the third quarter 2014 we shipped $68 thousand of NEXAFED® and we recognized revenue of $145 thousand for shipments to customers where the right of return no longer existed either because a pricing allowance was accepted in exchange for forfeiting the right of return or because information became available on pharmacy's reorder activity with their drug wholesaler. We will continue to analyze information to assess the recognition of our revenue but also expect to continue the deferral of some revenue from NEXAFED® in the foreseeable future.

C onference Call Information

Acura Pharmaceuticals, Inc. will host a conference call to discuss the results on Tuesday, November 4, 2014 at 8:30 a.m. ET.

To participate in the live conference call, please dial 1-888-428-9473 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 9602172. A replay of the call will be available beginning November 6, 2014 at 11:30 a.m. ET and ending on November 22, 2014 on the company's website.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX™ contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved our oxycodone HCl immediate- release tablets which incorporate the AVERSION® Technology. The Company has a development pipeline of additional AVERSION® Technology products containing other opioids.

In December 2012, the Company commenced commercialization of NEXAFED® (pseudoephedrine HCl), a 30 mg immediate-release abuse-deterrent decongestant. This next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE® Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:

  • the results of our dispute resolution request with the FDA, including any appeals therefrom, relating to our AVERSION® hydrocodone/acetaminophen product;
  • the results of our development of our LIMITX™ technology;
  • our ability to fund, or obtain funding for, products developed utilizing our LIMITX™ technology;
  • our ability to enter into a license agreement for our FDA approved AVERSION® oxycodone product;
  • our and our licensee's ability to successfully launch and commercialize our products and technologies including AVERSION® oxycodone and NEXAFED® Tablets;
  • the results of our meetings or discussions with the FDA relating to our AVERSION® hydrocodone/acetaminophen product;
  • whether the results of studies AP-ADF-302, AP-ADF-303, and AP-ADF-304 relating to our Aversion hydrocodone/acetaminophen product will be acceptable to the FDA;
  • whether we will conduct an additional intranasal abuse liability study on our AVERSION® hydrocodone/ acetaminophen product and, if conducted, whether the results of such study will support the filing of a New Drug Application and/or a claim of intranasal abuse deterrence;
  • our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
  • the market acceptance of and competitive environment for any of our products;
  • the willingness of wholesalers and pharmacies to stock NEXAFED® Tablets;
  • expectations regarding potential market share for our products and the timing of first sales;
  • our ability to enter into additional license agreements for our AVERSION® Technology product candidates;
  • our exposure to product liability and other lawsuits in connection with the commercialization of our products;
  • the increasing cost of insurance and the availability of product liability insurance coverage;
  • the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
  • the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
  • the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet OTC Monograph standards as applicable;
  • the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
  • changes in regulatory requirements;
  • adverse safety findings relating to our product candidates;
  • whether the FDA will agree with our analysis of our clinical and laboratory studies;
  • whether further studies of our product candidates will be required to support FDA approval;
  • whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies; and
  • whether our AVERSION® and LIMITX™ product candidates will ultimately deter abuse in commercial settings and whether our IMPEDE ® Technology will disrupt the processing of pseudoephedrine into methamphetamine.

In some cases, you can identify forward-looking statements by terms such as "may," "will", "should," "could," "would," "expects," "plans," "anticipates," "believes," "indicates," "estimates," "projects," "predicts," "potential," and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 
ACURA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
         
    (unaudited)   (audited)
    September 30,   December 31,
    2014   2013
Current assets   $ 16,143   $ 27,453
Property, plant and equipment, net     957     941
Other assets     180     236
Intangible asset     2,000     -
    Total assets   $ 19,280   $ 28,630
             
Current liabilities   $ 1,644   $ 820
Deferred revenue - current     228     287
Current maturities of long-term debt     1,160     -
Long-term portion of accrued interest     140     -
Long-term debt, net of debt discount of $311 and $400     8,529     9,600
Stockholders' equity     7,579     17,923
    Total liabilities and stockholders' equity   $ 19,280   $ 28,630
             
             
   
ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)  
(in thousands, except per share data)  
             
    Unaudited     Unaudited  
    Three Months     Nine Months  
    Ended September 30,     Ended September 30,  
    2014     2013     2014     2013  
Revenues:                                
  Royalty revenue   $ -     $ 3     $ 4     $ 8  
  Product sales, net     145       80       218       80  
    Total revenues, net     145       83       222       88  
Operating expenses:                                
  Cost of sales (excluding inventory write-down)     108       78       188       78  
  Inventory write-down     -       -       201       361  
  Research and development     955       1,289       3,674       4,120  
  Selling, marketing, general and administrative     1,728       1,941       5,903       6,138  
    Total operating expenses     2,791       3,308       9,966       10,697  
    Operating loss     (2,646 )     (3,225 )     (9,744 )     (10,609 )
Non-operating income (expense):                                
  Investment income     46       55       143       136  
  Loss on sales of marketable securities     -       (20 )     (5 )     (11 )
  Interest expense     (304 )     -       (907 )     -  
    Total other income (expense)     (258 )     35       (769 )     125  
    Loss before income taxes     (2,904 )     (3,190 )     (10,513 )     (10,484 )
  Provision for income taxes     -       -       -       -  
    Net loss   $ (2,904 )   $ (3,190 )   $ (10,513 )   $ (10,484 )
Other comprehensive income:                                
  Unrealized gains (losses) on securities     (44 )     114       6       35  
    Total other comprehensive income (expense)     (44 )     114       6       35  
    Comprehensive loss   $ (2,948 )   $ (3,076 )   $ (10,507 )   $ (10,449 )
                                     
Loss per share:                                
    Basic   $ (0.06 )   $ (0.07 )   $ (0.22 )   $ (0.22 )
    Diluted   $ (0.06 )   $ (0.07 )   $ (0.22 )   $ (0.22 )
Weighted average shares outstanding:                                
    Basic     48,922       47,458       48,871       47,297  
    Diluted     48,922       47,458       48,871       47,297  
                                 
                                 

Contact: for Acura Investor Relations Email contact 847-705-7709 for Acura Media Relations Email contact 847-705-7709

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 215

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 423

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 245

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 334

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

TransAlta Announces Right to Convert Series G Preferred Shares

Updated Category News Views 124

Update on TransAlta's Series G Preferred Shares TransAlta Corporation (TSX: TA; NYSE: TAC) has shared important news about its cumulative redeemable rate reset first preferred shares, known as Series G. The company has decided not to exercise its right to redeem these shares on the upcoming conversion date. Details on the Conversion of Series G Shares Holders of Series G...

Continue Reading
Automotive Engine Oil Market Surge: Innovations and Challenges

Updated Category News Views 469

The Rising Tide of the Automotive Engine Oil Market The global automotive engine oil market is on a exciting trajectory, projected to grow significantly in the coming years. This growth can largely be attributed to the increasing number of vehicles on the roads and advancements in engine oil technology. Experts estimate that the market will grow by approximately USD 12.5...

Continue Reading
Understanding Ferguson Enterprises' Price-to-Earnings Ratio

Updated Category News Views 112

Ferguson Enterprises Inc. Recent Stock Performance As we delve into Ferguson Enterprises Inc. (NYSE: FERG), the current trading price stands at $227.06, reflecting a slight decrease of 0.71%. In the preceding month, the stock has experienced a drop of 10.00%. However, when we take a year-long view, it’s noteworthy that the stock has actually appreciated by 30.82%. This...

Continue Reading
Cyabra to Engage in Needham Growth Conference: What to Expect

Updated Category News Views 100

Cyabra to Engage in Needham Growth Conference Cyabra Ltd., a pioneering AI platform focused on the detection of real-time disinformation, is set to participate in an influential industry event: the 27th Annual Needham Growth Conference. This virtual conference presents an exciting opportunity for investors and stakeholders to connect with Cyabra's leadership, specifically...

Continue Reading
Job Market Frustrations: The Truth Behind 'Remote Work' Claims

Updated Category News Views 451

Job Seekers Faces Misleading Remote Work Claims Recently, stories shared online illustrate a frustrating trend in the job market, particularly concerning remote work commitments. Job seekers are collectively expressing outrage over interviews that promise flexible arrangements only to reveal hidden requirements for in-office presence. This alarming shift has spurr

Continue Reading